Skip to main content

Advertisement

SpringerLink
Log in

Targeted Therapies for Follicular Lymphoma

  • T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Follicular lymphoma (FL) is the 2nd most common lymphoma in the USA/Western Europe. While incurable, the majority of patients are able to survive at least a decade with this disease. Response duration though varies, and subset of patients will relapse within 24 months of initial therapy (POD24). These patients have shortened survival compared to those who achieve more durable responses. Treatment interventions for patients are varied and include observation, radiation, or systemic therapies. Treatment outcomes have improved considerably over the last several decades with the introduction of new agents such as the CD 20 antibody rituximab and more recently with the advent of more targeted therapy. Most of the newer agents work differently from cytotoxic chemotherapy and either inhibit tumor-specific mutations, survival pathways, or harness the immune systems. While outcomes with traditional cytotoxic agents have been historically poor in certain subtypes such as POD24 and rituximab refractory disease, the reported outcomes with the newer agents have been encouraging as evident by several new drug approvals in FL. The biggest impact has been in the relapsed/refractory setting where we have approval of the immunomodulatory agent lenalidomide given in combination with rituximab. Based on the AUGMENT study, this agent has been approved for patients with R/R FL after one previous line of therapy. The EZH2 inhibitor, tazemetostat, was approved recently for patients with a known EZH2 mutation after one prior line of therapy or for FL patients who are deemed intolerant to other agents given the impressive safety profile in all patients. Finally, there is a plethora of agents that are designed to harness the immune system to combat this lymphoma. The data for these agents is still very early but nonetheless very impressive. In summary, FL is an incurable lymphoma without any standard of care options but has numerous treatments that have demonstrated some degree of efficacy. Recently we have made enormous strides in the understanding of some of the biological drivers of this disease which has allowed for refinement of treatment options. Moving forward, I would anticipate that we will continue to explore the use of agents that target specific mutations or utilize the immune system to hopefully one day achieve a cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Swerdlow SH, Campo E, Harris NL et al. Who classification of tumours of haematopoietic and lymphoid tissues.

  2. Centers for Disease Control and Prevention. United States Cancer Statistics. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Accessed 22 December 2020.

  3. Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110–7.

    Article  CAS  Google Scholar 

  4. Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haïoun C, et al. DOXOrubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998 Jul;16(7):2332–8.

    Article  Google Scholar 

  5. Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 2013;31(16):1977–83.

    Article  CAS  Google Scholar 

  6. Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51(5):1219–27.

    Article  CAS  Google Scholar 

  7. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–806.

    Article  Google Scholar 

  8. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237–45.

    Article  CAS  Google Scholar 

  9. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–47 Study that compared R2 to chemoimmunotherapy. While the study was negative from the planned objective, it did demonstrate that the efficacy of R2 was comparable to R-chemo in frontline patients.

  10.   Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10 The first of two studies that demonstrated the efficacy of BR in frontline FL and led to a marked increase in the use of bendamustine in iNHL.

  11. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.

    Article  CAS  Google Scholar 

  12. Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab (Br) for follicular lymphoma: a real world analysis across 13 us cancer centers. Blood. 2017;130(Supplement 1):2779.

    Google Scholar 

  13. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516–22.

    Article  CAS  Google Scholar 

  14. Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–101.

    Article  Google Scholar 

  15. Casulo C, Le-Rademacher J, Dixon J, et al. Validation of pod24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (Flash) investigation using individual data from 5,453 patients on 13 clinical trials. Blood. 2017;130(Supplement 1):412.

    Google Scholar 

  16. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164:811–21.

    Article  CAS  Google Scholar 

  17. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–35 [Erratum: Leukemia 26:2445, 2012].

    Article  CAS  Google Scholar 

  18. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: Implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–20.

    Article  CAS  Google Scholar 

  19. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–8.

    Article  CAS  Google Scholar 

  20. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–7.

    Article  CAS  Google Scholar 

  21. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11:5984–92.

    Article  CAS  Google Scholar 

  22. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126:50–60.

    Article  CAS  Google Scholar 

  23. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36–45.

    CAS  PubMed  Google Scholar 

  24. Leonard J, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–99 Study that led to the approval of R2 in R/R FL and MZL. This study results have established R2 as the preferred treatment in the 2nd line at this time.

    Article  Google Scholar 

  25. Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–65.

    Article  Google Scholar 

  26. Sehn L, Herrera AF, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B cell lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155–65.

    Article  CAS  Google Scholar 

  27. Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A phase i study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-hodgkin lymphoma. Clin Cancer Res. 2019 Dec 1;25(23):6986–94.

    Article  CAS  Google Scholar 

  28. Pongas G, Cheson BD. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol. 2016;43(6):647–54.

    Article  CAS  Google Scholar 

  29. Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020;4(13):3072–84.

    Article  CAS  Google Scholar 

  30. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24. https://doi.org/10.1038/nrc3860.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156–9.

    Article  Google Scholar 

  32. Gopal AK, Kahl BS, Flowers C, Martin P, Link BK, Ansell S, et al. Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy. Blood. 2015 Dec;126(23):2744.

    Article  Google Scholar 

  33. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–22.

    Article  CAS  Google Scholar 

  34. Swarup S, Quick DP, Sultan A, et al. Incidence of serious adverse events, pneumonitis, infection and sepsis in patients with relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with phosphatidylinositol 3-Kinase (PI3K) inhibitors. Oral presentation at: 61st ASH Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL. Abstract 798

  35.   Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905 Study the demonstrated efficacy of IV copanlisib and started current trend of reduced cumulative dosing of PI3Ki to reduce frequency of toxicities that had severely limited to utilization of these agents in R/R FL.

  36. Zelenetz AD, Jagadeesh D, et al. Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2019;37(15_suppl):7512.

    Article  Google Scholar 

  37. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36(23):2405–12.

    Article  CAS  Google Scholar 

  38. Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182–90.

    Article  CAS  Google Scholar 

  39. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen R, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study [abstract]. Blood. 2015;126(23):470.

    Article  Google Scholar 

  40. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.

    Article  CAS  Google Scholar 

  41. Devan J, Janikova A, Mraz M. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. Semin Oncol. 2018 Oct;45(5-6):291–302. https://doi.org/10.1053/j.seminoncol.2018.07.005.

    Article  CAS  PubMed  Google Scholar 

  42. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649–59.

    Article  CAS  Google Scholar 

  43. Dickinson M, Popplewell L, Kolstad A, et al. ELARA: a phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (R/r fl). JCO. 2019;37(15_suppl):TPS7573-TPS7573.

  44. Min Kim T, Alonso A et al: A phase 2 study of odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-hodgkin lymphoma. ASH 2020 Abstract 3029

  45. Assouline SE, Kim WS et al: Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. ASH 2020 Abstract 702

  46. Hutchings M, Carlo-Stella C et al: Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. ASH 2020 Abstract 403

  47. Jacobson C Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients with relapsed/refractory (R/r) indolent non-hodgkin lymphoma(Inhl). In: ASH; 2020.

  48. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019;380(1):45–56.

    Article  CAS  Google Scholar 

  49.   Morschhauser F, Tilly H, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–42 Study that led to the approval of tazemetostat in patients with R/R FL who have a known EZH2 mutation or are unable to tolerate other treatment options providing another well-tolerated option for patients with R/R FL and further advances utilization of molecular testing to target specific genetic changes that drive lymphomas.

Download references

Author information

Authors and Affiliations

  1. Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48130, USA

    Jennifer Girard, Yasmin Karimi, Shannon Carty, Ryan Wilcox, Mark Kaminiski, Sami Malek & Tycel Phillips

Authors
  1. Jennifer Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasmin Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shannon Carty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryan Wilcox
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Kaminiski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sami Malek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tycel Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tycel Phillips.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Indexing: Indexed in PubMed, Web of Science, Scopus, and more

This article is part of the Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Girard, J., Karimi, Y., Carty, S. et al. Targeted Therapies for Follicular Lymphoma. Curr Hematol Malig Rep 16, 25–31 (2021). https://doi.org/10.1007/s11899-021-00614-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-021-00614-8

Keywords

Search

Navigation